Influence of quality control circle on the hospital delay time in patients with acute ischemic stroke
-
摘要: 目的: 探讨品管圈对缩短急性缺血性卒中患者静脉溶栓治疗院内延误时间的作用。方法: 收集2017-03-2017-10期间我院急诊纳入绿色通道的缺血性卒中患者140例, 按随机法分为对照组70例, 采用常规流程救治;观察组70例, 采用品管圈优化流程救治。以静脉溶栓成功率、入院至治疗时间 (DNT) 达标率、入院至评估时间、入院至获得影像结果时间、入院至获得实验室结果时间以及入院至治疗中位数时间为指标, 比较俩组数据差异。结果: 观察组患者静脉溶栓成功率及DNT达标率明显高于对照组 (P<0.05), 入院至治疗中位数时间、入院至评估时间、入院至获得影像结果时间明显短于对照组 (P<0.05), 入院至获得实验室结果时间差异无统计学意义 (P>0.05)。结论: 通过实施品管圈活动优化了绿色通道流程, 使患者静脉溶栓成功率及DNT达标率明显提高, 可有效减少院内治疗延误时间。Abstract: Objective: To explore the influence of quality control circle (QCC) on shortening the hospital delay time for starting intravenous thrombolytic therapy in patients with acute ischemic stroke (AIS).Method: From March 2017 to October 2017, 70 AIS patients without QCC in our hospital were selected as the control group, and70 patients with QCC were selected as the observation group.The success rate of thrombolytic therapy and the time for door to needle (DNT), evaluation, image, andlaboratory test were observed and compared between two groups.Result: The success rate of thrombolytic therapy was significantly higher in observation group than that in control group (P<0.05).In observation group, the time for door to needle, evaluation and image was significantly shorter than those in control group (P<0.05).And there was no significant difference in the timefor door to laboratory test between the two groups (P>0.05).Conclusion: The application of QCC can optimize the process of thrombolytic therapy, shorten the DNT time and improve the success rate of thrombolytic therapy.It can effectively reduce the delay time of hospital treatment of AIS patients.
-
-
[1] Liu L, Wang D, Wong K S, et al.Stroke and stroke care in China:huge burden, significant workload, and a national priority[J].Stroke, 2011, 42:3651-3654.
[2] 胡贝贝, 杨丽黎, 江云, 等.脑卒中专科护士角色的设立及实践[J].中华护理杂志, 2017, 52 (10):1195-1199.
[3] 高峰, 繆中荣, 刘亚杰.急性缺血性脑卒中血管内治疗中国专家共识[J].中国脑血管病杂志, 2014, 11 (10):556-560.
[4] Wardlaw J M, Murray V, Berge E, et al.Recombinant tissue plasminogen activator for acute ischaemic stroke:an updated systematic review and meta-analysis[J].Lancet, 2012, 379:2364-2372.
[5] 重组组织型纤溶酶原激活剂治疗缺血性卒中共识专家组.重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中中国专家共识 (2012版)[J].中华内科杂志, 2012, 51 (12):1006-1010.
[6] 潘璐, 谢小华, 谭薇, 等.急性缺血性脑卒中病人急诊静脉溶栓干预措施及效果评价[J].护理研究, 2017, 31 (9):1079-1082.
[7] Jauch E C, Saver J L, Adams H P, et al.Guidelines for the early management of patients with acute ischemic stroke:aguideline for healthcare professionals from the American heart association/American stroke association[J].Stroke, 2013, 44:870-947.
[8] Fonarow G C, Zhao X, Smith E E, et al.Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative[J].JAMA, 2014, 311:1632-1640.
[9] 郑少燕, 黄旭华, 陈少芸, 等.品管圈在外来手术器械持续质量改进中的应用研究[J].临床急诊杂志, 2017, 18 (4):307-309.
[10] 李晶晶, 佟旭, 曹亦宾.急性缺血性卒中静脉溶栓治疗院前和院内延误现状分析[J].中国卒中杂志, 2016, 11 (11):991-996.
[11] 李楠.优化缺血性卒中绿色通道流程对院内无缝衔接急救模式的临床研究[J].中国卒中杂志, 2017, 12 (8):696-700.
[12] 栾梅, 文治成.急性缺血性脑卒中患者复发危险因素分析及预后指数模型构建[J].临床急诊杂志, 2016, 17 (8):610-613.
[13] Saver J L, Fonarow G C, Smith E E, et al.Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke[J].Jama J Am Med Associat, 2013, 309:2480-2488.
[14] 黄镪, 宋海庆, 吉训明, 等.院前预通知对急性缺血性卒中患者静脉溶栓治疗院内延误的影响[J].中国脑血管病杂志, 2016, 13 (4):182-186.
[15] 罗高权, 项薇, 武肖娜, 等.优化诊疗流程在急性缺血性脑卒中患者救治中的价值[J].临床急诊杂志, 2017, 18 (12):946-950.
[16] Saver J L, Fonarow G C, Smith E E, et al.Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke[J].JAMA, 2013, 309:2480-2488.
[17] 张琳, 朱晓萍, 刘贤亮, 等.护士主导的急性缺血性脑卒中患者血管再通流程的优化及效果评价[J].中华护理杂志, 2017, 52 (4):449-453.
[18] 章飞雪, 于燕燕, 徐枝楼, 等.品管圈活动在精神科老年病房基础护理质量管理中的作用[J].中华护理杂志, 2013, 48 (2):127-130.
[19] 张娅梅.品管圈在缩短急性缺血性脑卒中行动脉溶栓治疗时间上的运用[J].当代护士, 2016, 10 (2):46-48.
[20] 陈洁, 窦梦娇, 杜彬, 等.品管圈在缩短急性缺血性脑卒中患者静脉溶栓诊疗时间上的应用[J].介入放射学杂志, 2016, 25 (1):81-84.
-
计量
- 文章访问数: 281
- PDF下载数: 272
- 施引文献: 0
下载: